Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 19/20 | 0.73 |
| ▸ | ADAM17 | P78536 | 10/20 | 0.73 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 2/20 | 0.57 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901340 | 0.93 | ADAMTS5 (0.73) | ADAMTS5ADAM17MMP2MMP1ADAMTS4 | |
| SCHEMBL23901408 | 0.89 | ADAMTS5 (0.71) | ADAMTS5ADAM17MMP2MMP1 | |
| SCHEMBL23901338 | 0.85 | ADAMTS5 (0.71) | ADAMTS5ADAM17MMP2 | |
| SCHEMBL17871242 | 0.85 | ADAMTS5 (1.00) | ADAMTS5ADAM17MMP2MMP1 | |
| SCHEMBL23901404 | 0.84 | ADAMTS5 (0.71) | ADAMTS5ADAM17MMP2MMP1ADAMTS4 | |
| SCHEMBL22201043 | 0.83 | ADAMTS5 (0.57) | ADAMTS5ADAM17MMP2MMP1 | |
| SCHEMBL23901304 | 0.81 | ADAMTS5 (0.75) | ADAMTS5ADAM17MMP2MMP1ADAMTS4 | |
| SCHEMBL17871383 | 0.79 | ADAMTS5 (1.00) | ADAMTS5ADAM17MMP2MMP1ADAMTS4 | |
| SCHEMBL23901276 | 0.79 | ADAMTS5 (0.75) | ADAMTS5ADAM17MMP2 | |
| SCHEMBL21582717 | 0.78 | ADAMTS5 (1.00) | ADAMTS5ADAM17MMP2MMP1ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941117-B2 | 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2021-03-09 | — | — | US | disclosed |
| US-20200216397-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216397-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | ADAMTS5 2/4885ADAM17 8/4885MMP2 53/4885 |
| US-10941117-B2 | 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS5, ADAMTS1, ADAMTS7 | ADAMTS5 1/4885ADAM17 8/4885MMP2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.